Overview

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Oncology Research International
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Erlotinib Hydrochloride